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Mito-priming as a method to engineer Bcl-2
addiction
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Most apoptotic stimuli require mitochondrial outer membrane permeabilization (MOMP) in
order to execute cell death. As such, MOMP is subject to tight control by Bcl-2 family
proteins. We have developed a powerful new technique to investigate Bcl-2-mediated
regulation of MOMP. This method, called mito-priming, uses co-expression of pro- and
anti-apoptotic Bcl-2 proteins to engineer Bcl-2 addiction. On addition of Bcl-2 targeting
BH3 mimetics, mito-primed cells undergo apoptosis in a rapid and synchronous manner.
Using this method we have comprehensively surveyed the efﬁcacy of BH3 mimetic
compounds, identifying potent and speciﬁc MCL-1 inhibitors. Furthermore, by combining
different pro- and anti-apoptotic Bcl-2 pairings together with CRISPR/Cas9-based genome
editing, we ﬁnd that tBID and PUMA can preferentially kill in a BAK-dependent manner.
In summary, mito-priming represents a facile and robust means to trigger mitochondrial
apoptosis.
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F
ollowing most apoptotic stimuli, mitochondrial outer
membrane permeabilization (MOMP) is essential for cell
death. MOMP leads to the release of mitochondrial
intermembrane space proteins such as cytochrome c that activate
caspase proteases causing rapid cell death1. However, even in the
absence of caspase activity, MOMP typically kills cells and
therefore represents a point-of-no-return2. Given this pivotal role
in dictating life and death, MOMP is highly regulated, primarily
by pro- and anti-apoptotic members of the Bcl-2 protein family3.
Evasion from apoptosis is considered a hallmark of cancer4.
Paradoxically, while apoptotic inhibition promotes cancer,
tumour cells often display increased apoptotic sensitivity
relative to normal tissue. Underlying this increased sensitivity,
are altered levels of pro- and anti-apoptotic Bcl-2 proteins. Due to
the pro-apoptotic stresses that cancer cells encounter, anti-
apoptotic Bcl-2 function is required for cell survival to counteract
pro-apoptotic BH3-only protein function. Cancer cells in this
state are termed ‘primed-to-die’ and are sensitive to apoptosis-
inducing therapies5,6. Importantly, targeted anti-cancer therapies
called BH3 mimetics have recently been developed to exploit this
Bcl-2 dependency. In a manner similar to BH3-only proteins,
BH3 mimetics bind to and inhibit anti-apoptotic Bcl-2 function7.
Due to the wide-ranging roles of apoptosis in health and
disease, the regulation of MOMP by Bcl-2 proteins has been
intensively studied. Nevertheless, methods to investigate
mitochondrial apoptosis are complicated by commonly used
treatments, such as staurosporine, that induce MOMP over many
hours, in an asynchronous manner and often with off-target,
non-MOMP-dependent effects. Current methods to ‘cleanly’
induce mitochondrial apoptosis include ER/tamoxifen or
doxycycline-based induction of BH3-only protein activity8–11.
However, these approaches remain far from ideal due to various
factors that include low potency, lack of general applicability,
extended time of induction and, in some cases, direct effects
of the chemical inducer on mitochondrial function12.
Circumventing these problems, our aim was to develop a
technique that would rapidly and synchronously induce
apoptosis over a cellular population in an effective manner.
Ideally, such an approach would be applicable to any cell of
choice. A second criterion was that any technique should also
permit investigation of Bcl-2-mediated regulation of MOMP, for
example allowing investigation of BH3-only protein speciﬁcity for
the executioner proteins BAX or BAK.
With these goals in mind, we chose to mimic primed-to-die
cancer cells through a method we call ‘mito-priming’. We
reasoned that co-expression of pro- and anti-apoptotic Bcl-2
proteins should render cells highly sensitive to the addition of
BH3 mimetic compounds (Fig. 1a). Bcl-2/BH3-only protein
complexes are highly dynamic; therefore, we predicted that
addition of BH3 mimetics that compete for Bcl-2 binding would
free sufﬁcient BH3-only proteins to activate BAX/BAK, leading to
MOMP and to cell death. Our expectation was that mito-priming
should permit engineering of Bcl-2 addiction to any cell-type.
Indeed, we ﬁnd that mito-priming is a potent and generally
applicable method to induce mitochondrial apoptosis in a clean
and controllable manner. Furthermore, mito-priming represents
a robust means of interrogating functional relationships within
the Bcl-2 family network. We highlight the utility of this method
to compare the potency and selectivity of available BH3 mimetics
and to identify selective requirements for the proapoptotic
effectors BAX and BAK in BH3-only protein driven apoptosis.
Results
Mito-priming permits rapid induction of apoptosis. In the
mito-priming method, we predicted that co-expression of
pro- and anti-apoptotic Bcl-2 proteins should enforce a Bcl-2
survival dependency on cells (Fig. 1a). To test this, the BH3-only
protein tBID (fused to GFP) was expressed together with anti-
apoptotic BCL-xL, using a 2A self-cleaving peptide sequence to
enable equimolar co-expression13. SVEC cells stably expressing
GFP–tBID 2A BCL-xL were generated by retroviral transduction
and ﬂow-cytometry-based cell sorting. Western blot analysis
veriﬁed expression of both GFP–tBID and BCL-xL, and confocal
microscopy demonstrated mitochondrial localization of GFP–
tBID, which was conﬁrmed by a high Pearson’s co-efﬁcient
of co-localization with Mitotracker Deep Red FM (Fig. 1b,
Supplementary Fig. 1a). We next determined the apoptotic
sensitivity of GFP–tBID 2A BCL-xL expressing cells following
treatment with the prototypic BH3 mimetic, ABT-737 (ref. 14).
Cell viability was determined by live-cell imaging and SYTOX
Green exclusion (Fig. 1c). Importantly, ABT-737 treatment
rapidly induced cell death in GFP–tBID 2A BCL-xL expressing
cells in a synchronous and concentration-dependent manner
(Fig. 1c, Supplementary Movies 1 and 2). In line with an on-target
effect, treatment with ABT-737 alone, but not its less-active
enantiomer, caused cell death (Supplementary Fig. 1b). Moreover,
BH3 mimetic-induced death was dependent upon active tBID,
since ABT-737 treatment of cells expressing an inactive mutant of
tBID (G94E)15 together with BCL-xL failed to trigger cell death
as determined by both long- or short-term survival assays
(Fig. 1d, Supplementary Fig. 1c,d). Consistent with engagement
of mitochondrial apoptosis, ABT-737 treatment led to
mitochondrial cytochrome c and SMAC release (as a readout of
MOMP) (Fig. 1e, Supplementary Movie 3) and caspase activity
(as veriﬁed by western blot analysis of PARP cleavage)
in a concentration-dependent manner (Fig. 1f). Furthermore,
inhibition of caspase function following treatment with the
pan-caspase inhibitor quinolyl-valyl-O-methylaspartyl-[2,6-
diﬂuorophenoxy]-methyl ketone (Q-VD-OPh) (Supplementary
Fig. 1e) or by small-hairpin-RNA-mediated knockdown of
APAF-1 effectively suppressed ABT-737-induced cell death,
conﬁrming engagement of mitochondrial apoptosis (Fig. 1g and
Supplementary Fig. 1f). Finally, we examined the general utility of
this method in other cell lines. For this purpose, we generated
HeLa, E1A/Ras transformed murine embryonic ﬁbroblasts
and 3T3-SA cells stably expressing GFP–tBID 2A BCL-xL
(Supplementary Fig. 1g,h). Stably expressing cells were treated
with ABT-737 or enantiomer and analysed for cell viability by
SYTOX Green exclusion. Following ABT-737 treatment, all three
cell types efﬁciently died in a manner that was dependent on
GFP–tBID 2A BCL-XL expression (Fig. 1h). These results
demonstrate that mito-priming is an effective way to engineer
Bcl-2 addiction in vitro. Following BH3 mimetic treatment, it
provides an easy and robust way to induce mitochondrial-
dependent apoptosis in a rapid and synchronous manner,
avoiding off-target effects inherent to commonly used treatments.
Applying mito-priming to characterize BH3 mimetics. We
reasoned that mito-priming would be ideally suited to determine
the selectivity and potency of different BH3 mimetics on an
identical cellular background. For this purpose, we generated
SVEC cells co-expressing GFP-tBID in combination with BCL-2,
BCL-xL or MCL-1, hereafter referred to as BCL-2-, MCL-1- or
BCL-xL-dependent cells. Mito-primed cells were treated with
increasing concentrations of the BCL-2/BCL-xL targeting BH3
mimetics, ABT-737 or ABT-263, the BCL-2 targeting BH3
mimetic ABT-199 or the BCL-xL-directed BH3 mimetics, WEHI-
539, A-1155463 or A-1331852 (Fig. 2a,b)14,16–19. Cell viability
was measured by live-cell imaging and SYTOX Green exclusion.
Verifying their on-target selectivity, ABT-737 and  263
efﬁciently killed both BCL-xL- and BCL-2-dependent cells,
ABT-199-induced death speciﬁcally in BCL-2-dependent cells
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Figure 1 | Mito-priming as a method of induced Bcl-2 addiction. (a) Method outline. (b) SVEC cells expressing eGFP-tBID 2A BCL-xL or other constructs
were co-stained with MitoTracker Deep Red. Colocalization was quantiﬁed using the Pearson’s coefﬁcient. Representative images show eGFP-tBID
expression and MitoTracker Deep Red staining from SVEC cells stably expressing eGFP-tBID 2A BCL-xL. Scale bar, 10 mm. (c) SVEC cells expressing eGFP-
tBID 2A BCL-xL were treated with ABT-737 and analysed for cell viability using an IncuCyte imager and SYTOX Green exclusion. Percentage cell death was
calculated by normalizing against maximal cell death (13-h treatment with 10 mmol l 1 ABT-737). Error bars represent the standard error of the mean
(s.e.m.) from three independent experiments. (d) SVEC cells stably expressing the indicated constructs were treated with increasing concentrations of
ABT-737 (mmol l 1; 24 h) and assayed for clonogenic survival. Error bars represent the s.d. of triplicate samples from a representative experiment carried
out twice independently. (e) SVEC cells stably expressing indicated constructs were treated with increasing concentration of ABT-737 (mmol l 1) for 6 h
with 10mmol l 1 ABT-737 in presence of Q-VD-OPh. Cells were quantiﬁed for cytochrome c release by confocal microscopy. Error bars represent the s.e.m.
of three independent experiments. (f) SVEC cells stably expressing the indicated constructs were treated for 6 h with ABT-737 (mmol l 1). PARP and
caspase-3 cleavage was determined by western blot. Actin was probed as a loading control. (g) SVEC cells stably expressing the indicated constructs were
treated for 13 h with 10mmol l 1 ABT-737 or enantiomer (ENA). Cell viability was determined as in c. Percentage cell death was calculated by normalizing
against 100% cell death (24-h treatment with 1 mmol l 1 actinomycin D). (h) Cell lines stably expressing control vector (pLKO1) or two independent shRNA
sequences targeting APAF-1 were treated for 16 h with enantiomer (ENA) or ABT-737. 100% death: 24-h treatment with 1 mmol l 1 actinomycin D (for
each line). Cell viability was determined as in c. Percentage cell death was calculated by normalizing against 100% cell death (24-h treatment with
1mmol l 1 actinomycin D). In g,h error bars represent the s.e.m. of three independent experiments. See also Supplementary Fig. 1 and Supplementary
Movies 1–3. Q-VD-OPh, quinolyl-valyl-O-methylaspartyl-(2,6-diﬂuoro- phenoxy)-methyl ketone.
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and WEHI-539, A-1155463 and A-1331852 speciﬁcally killed
BCL-xL-dependent cells (Fig. 2c,d). Moreover, none of these BH3
mimetics induced cell death in the MCL-1-dependent SVEC cells
(Supplementary Fig. 2a,b). The highly selective cytotoxic effect of
all BH3 mimetics was also apparent by long-term clonogenic
survival assay (Fig. 2e,f). Notably, supporting previous ﬁndings,
the dual-BCL-xL/BCL-2 inhibitors ABT-737 and ABT-263
induced death more effectively in BCL-2-dependent cells
compared with BCL-xL-dependent cells (Fig. 2c,d)11,20. Our
method also allowed direct comparison of BH3 mimetic potency
within a speciﬁc Bcl-2-dependent cell line. This revealed that
WEHI-539, A-1155463 and A-1331852 and ABT-199 were more
effective at inducing death in their cognate target SVEC cells
compared to the dual-BCL-2/BCL-xL inhibitors, ABT-263 and
ABT-737 (Fig. 2c–f). Furthermore, direct comparison between
BCL-xL targeting BH3 mimetics demonstrated that A-1155463
and A-1331852 were signiﬁcantly more potent than WEHI-539
(Fig. 2c–f). This was further supported by analysing cell viability
over an extended concentration range, revealing EC50 values
of approximately 500 and 100 nmol l 1 for A-1155463 and
A-1331852 respectively, compared with 2.5 mmol l 1 of
WEHI-539 (Fig. 2g and Supplementary Fig. 2c). At maximally
effective doses, A-1155463, A-1331852 and WEHI-539 displayed
high selectivity for BCL-xL whereas at higher levels
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Figure 2 | Applying mito-priming to deﬁne the selectivity and potency of BH3 mimetics. (a) Predicted pattern of inhibition by different BH3 mimetics
tested. (b) Western blot analysis of SVEC cells stably expressing eGFP-tBID 2A BCL-xL, eGFP-tBID 2A BCL-2 or eGFP-tBID 2A MCL-1. * denotes ectopically
expressed MCL-1. (c,d) SVEC cells stably expressing eGFP-tBID 2A BCL-xL (BCL-xL-dependent line) or eGFP-tBID 2A BCL-2 (BCL2-dependent line) were
treated with increasing concentrations of different BH3 mimetics. Cell viability was determined by SYTOX Green dye exclusion and live-cell imaging using
an IncuCyte imager. Error bars represent the s.e.m. of three independent experiments. (e,f) BCL-xL (e) or BCL-2-dependent lines (f) were treated with
increasing concentrations of different BH3 mimetics and analysed for long-term survival by clonogenic assay. Percentage clonogenic survival is plotted
relative to untreated cells. Error bars represent the s.d. of triplicate samples from a representative experiment carried out twice independently. (g) BCL-xL-
dependent line was treated with increasing concentrations of BCL-xL-directed BH3 mimetics. Cell viability was determined by SYTOX Green dye exclusion
and live-cell imaging using an IncuCyte imager. Errors bars represent the s.e.m. of three independent experiments. See also Supplementary Fig. 2.
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(5–10 mmol l 1 ) some off-target toxicity for was also observed
for A-1331852 in BCL-2-dependent cells (Fig. 2d). These data
demonstrate that mito-priming can be used to render cell viability
dependent on any given Bcl-2 prosurvival family member. In
doing so, this permits rapid analysis of both the potency and
selectivity of BH3 mimetic compounds.
Mito-priming deﬁnes potent MCL-1 targeting BH3 mimetics.
Intense interest surrounds the development of MCL-1 inhibitors
mainly because current, clinically relevant BH3 mimetics do not
target MCL-1. We aimed to use our line stably expressing
GFP–tBID 2A MCL-1 to investigate the potency and selectivity of
MCL-1 targeted BH3 mimetics. We ﬁrst conﬁrmed the MCL-1
dependency of these cells by transient expression of NOXA,
a BH3-only protein that selectively binds to and inhibits
MCL-1 prosurvival function21. Accordingly, NOXA expression
preferentially killed MCL-1-dependent SVEC cells (Fig. 3a).
Next, we investigated the potency of two recently described
MCL-1 inhibitors, UMI-77 and A-1210477 (refs 22,23). MCL-1-
dependent SVEC cells were treated with varying doses of each
inhibitor and assayed for cell viability by SYTOX Green exclusion
and live-cell imaging. Both inhibitors induced cell death in the
MCL-1-dependent line in a dose-dependent manner (Fig. 3b).
Notably, A-1210477 was signiﬁcantly more potent than UMI-77,
with an EC50 below 5 mmol l 1 compared with 10mmol l 1 for
UMI-77 (Fig. 3b). In line with increased potency, A-1210477 also
induced cell death more rapidly (Fig. 3c). The selectivity of these
two compounds for targeting MCL-1 over other Bcl-2 family
members was next examined. BCL-2-, BCL-xL- and MCL-1-
dependent SVEC cells were treated with either inhibitor and
assayed for cell viability by short-term, SYTOX Green exclusion
and long-term clonogenic survival assay. Both inhibitors
preferentially killed MCL-1-dependent SVEC cells, attesting to
their on-target speciﬁcity (Fig. 3d,e). Whereas A-1210477
solely killed MCL-1-dependent cells, UMI-77 also displayed
limited toxicity in BCL-2-dependent SVEC cells (Fig. 3d,e)
demonstrating that UMI-77 also affects BCL-2 prosurvival
function. Using our approach of induced MCL-1 addiction, our
data demonstrate that both UMI-77 and A-1210477 are effective
and speciﬁc MCL-1 inhibitors, with A-1210477 displaying greater
potency and speciﬁcity.
tBID and PUMA can display a dependence on BAK to kill. The
active form of BID (tBID), BIM and possibly PUMA, represent a
subset of BH3-only proteins, called activators, that directly acti-
vate the effector proteins BAX and BAK, causing mitochondrial
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Figure 3 | Mito-priming deﬁnes potent and speciﬁc MCL-1 targeting BH3 mimetics. (a) SVEC cells stably expressing FLAG-tBID 2A GFP-BCL-xL, FLAG-
tBID 2A GFP-BCL-2 or FLAG-tBID 2A GFP-MCL-1 were transiently transfected with NOXA. Cell viability was analysed 24 h post-transfection by SYTOX
Green dye exclusion and live-cell imaging using an IncuCyte imager. Error bars represent the s.e.m. of three independent experiments. (b) SVEC cells stably
expressing FLAG-tBID 2A GFP-MCL-1 (MCL-1-dependent line) were treated with increasing concentrations of putative MCL-1 inhibitors UMI-77 or
A-1210477. Cell viability was analysed 24h post-treatment by SYTOX Green dye exclusion and live-cell imaging using an IncuCyte imager. Error bars
represent the s.e.m. of three independent experiments. (c) MCL-1-dependent line was treated with UMI-77 or A-1210477 (both 10mmol l 1) and analysed
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independent experiments. (d,e) SVEC cells stably expressing FLAG-tBID 2A GFP-BCL-xL, FLAG-tBID 2A GFP-BCL-2 or FLAG-tBID 2A GFP-MCL-1 were
treated with UMI-77 or A-1210477 (10mM for 24 h) then cell viability was analysed by SYTOX Green dye exclusion and live-cell imaging using an IncuCyte
imager (d) or by clonogenic survival assay (e). Error bars represent the s.e.m. of three independent experiments for d and s.d. of triplicate samples from a
representative experiment carried out twice independently for e. In all cases, cells were treated with MCL-1 inhibitors in 3% FBS containing DMEM.
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permeabilization and cell death. Recently, tBID and BIM have
been shown to display selectivity for BAK over BAX, although
whether this also holds true for PUMA remains untested24. To
investigate this, we applied our approach of mito-priming in
BAX-, BAK- or BAX/BAK-deleted cells (Fig. 4a). SVEC cells
stably co-expressing tBID, BIMs or PUMA together with BCL-xL
were generated (Supplementary Fig. 3a). In stable lines expression
levels of PUMA were highest followed by BIMs and tBID. Next,
CRISPR-/Cas9-based genome editing was used to delete BAX
and/or BAK (Fig. 4b). Cells were treated with ABT-737 and
assayed for cell viability by live-cell imaging and SYTOX Green
exclusion or by long-term clonogenic survival assay. As expected,
combined deletion of BAX and BAK prevented cell death in all
cases (Fig. 4c,d). Importantly, whereas BIM-induced death
displayed no selectivity, speciﬁc deletion of BAK effectively
protected against tBID- and PUMA-induced cell death in both
short- and long-term viability assays (Fig. 4c,d). Conﬁrming
BAK-dependent selectivity and on-target genome editing,
reconstitution of BAK CRISPR-edited SVEC cells with BAK
restored sensitivity to tBID and PUMA killing, (Fig. 4e and
Supplementary Fig. 3b). These data demonstrate that PUMA and
tBID selectively require BAK to induce apoptosis in this cell-type.
Further supporting this, caspase activity (determined by western
blotting for PARP and caspase-3 cleavage), was substantially
reduced speciﬁcally in BAK-deﬁcient cells following ABT-737
treatment (Fig. 4f). After ABT-737 addition, BCL-xL complexed
to either PUMA or BIMs was signiﬁcantly reduced, as determined
by immunopreciptation (Supplementary Fig. 3c). Supporting a
transient ‘hit-and-run’ interaction, no direct interaction between
BIMs or PUMA with BAX or BAK could be detected by
immunoprecipitation. To conﬁrm that tBID selectivity for BAK
was not due to co-expression of BCL-xL we carried out similar
experiments in BCL-2-dependent cells. Using CRISPR/Cas9
genome editing, BAK, BAX or BAK and BAX were deleted in
GFP–tBID-2A-BCL-2-expressing SVEC cells (Supplementary
Fig. 3d). Cells were treated with varying concentrations of
ABT-199 and assessed for cell death by SYTOX Green exclusion
and live-cell imaging. Importantly, in line with previous results,
deletion of BAK or BAX and BAK effectively prevented
tBID-induced death, whereas deletion of BAX had little effect
(Fig. 4g). Finally, we generated HeLa cells expressing GFP-tBID
2A BCL-xL, GFP-PUMA 2A BCL-xL or GFP-BIMs 2A BCL-xL
that were deﬁcient in BAX, BAK or BAX and BAK and tested their
sensitivity to ABT-737 treatment (Fig. 4h, Supplementary Fig. 3e).
In contrast to our previous results, deletion of either BAX or BAK
conferred a similar level of protection against tBID and PUMA
induced death in HeLa cells, arguing against a selective preference
for either BAX or BAK in this setting (Fig. 4h). BAX levels were
similar between different cell types ruling this out as a
determinant of selectivity (Supplementary Fig. 3f). Interestingly,
unlike SVEC cells, HeLa cells expressing GFP-BIMs 2A BCL-xL,
poorly responded to ABT-737 treatment (Fig. 4h). Of note, a
failure to disrupt BIM/BCL-xL complexes by ABT-737 treatment
has also been observed by others25. Along these lines, possibly
accounting for this resistance, co-immunoprecipitation analysis
revealed that ABT-737 treatment failed to disrupt the interaction
between BIMs and BCL-xL, (Supplementary Fig. 3g). By
combining mito-priming with CRISPR/Cas9-mediated genome
editing, our results demonstrate that BH3-only proteins can
exhibit a preference for BAK over BAX in some cellular contexts.
While previously observed for tBID, we also ﬁnd a similar
preference for BAK by PUMA.
Mapping determinants of BAK-dependent apoptosis. The
selective requirement of tBID and PUMA for BAK may be due to
a preferential ability to activate BAK or an inability to oppose
neutralization of BAX by anti-apoptotic Bcl-2 family members.
To discriminate these possibilities, we investigated whether
PUMA and tBID also displayed selectivity for BAK in the absence
of anti-apoptotic Bcl-2 co-expression. To this end, GFP–tBID
and GFP–PUMA were transiently expressed in BAX and/or
BAK-deleted SVEC cells. In line with our earlier ﬁndings, tBID
and PUMA still preferentially killed in a BAK-dependent manner
(Fig. 5a). In a separate approach, we examined whether combined
neutralization of MCL-1, BCL-xL and BCL-2 had any effect on
the BAK dependency of tBID-induced killing. For this purpose,
we used BAX and/or BAK CRISPR-edited SVEC cells that were
stably expressing GFP tBID 2A BCL-xL. Cells were treated with a
combination of A-1331852, A-1210477 and ABT-199 to neu-
tralize anti-apoptotic Bcl-2 function and analysed for cell viability
by SYTOX Green exclusion and live-cell imaging (Fig. 5b).
Importantly, irrespective of pan-Bcl-2 inhibition, tBID-induced
cell death still displayed BAK dependence. Similar results were
obtained for PUMA-induced cell death (Fig. 5c). Collectively,
these data argue that the dependency of tBID and PUMA for
BAK is direct and not through differential neutralization of anti-
apoptotic Bcl-2 proteins. We next determined whether BH3-only
protein selectivity for BAK was an intrinsic property of one or
both proteins. To this end, mitochondria were isolated from
SVEC cells stably expressing GFP-tBID 2A BCL-xL that were
BAK or BAK/BAX deleted. Mitochondria from BAX/BAK-deleted
cells were treated with recombinant BAX in the presence or
absence of recombinant tBID or ABT-737. Alternatively,
mitochondria from BAK-deleted cells were treated with tBID or
ABT-737. Mitochondrial permeabilization was assessed by
western blotting for cytochrome c (Fig. 5d). Importantly,
recombinant BAX in combination with tBID or ABT-737
effectively permeabilized mitochondria from BAX/BAK-deleted
cells. Moreover, tBID or ABT-737 treatment effectively
permeabilized mitochondria from BAK-deleted cells, where
residual BAX permitted permeabilization (Fig. 5d, Supplementary
Fig. 4). Given that BAK deletion effectively prevented
tBID-induced killing (Fig. 4c, Supplementary Fig. 3b) these data
demonstrate that an intact cellular environment is required for
the selective dependence of tBID on BAK. Finally, they argue
that the differential requirement for BAX or BAK by speciﬁc
BH3-only proteins lies at the point of activation of these effectors,
as opposed to effects on anti-apoptotic Bcl-2 function.
BH3-only dependency on BAK is dictated by the BH3-domain.
We next focused on the BH3-domain as a possible determinant of
BAX/BAK speciﬁcity. Our earlier results demonstrated that BIMs
displayed no selective requirement for BAX or BAK. Therefore,
we initially decided to swap the BH3 domains between tBID and
BIMs and ask whether this affected BAX/BAK selectivity. SVEC
cells stably expressing tBIDBIM BH3 or BIMtBID BH3 together with
BCL-xL were generated (Fig. 6a) then BAX and/or BAK were
deleted by CRISPR/Cas9-based genome editing (Supplementary
Fig. 5a). Cells were treated with ABT-737 and monitored for cell
viability by short-term SYTOX Green exclusion/live-cell imaging
or by long-term clonogenic survival assay (Fig. 6b,c). Strikingly,
BIMs encoding the BID BH3 domain displayed an absolute
dependence on BAK to kill cells. This contrasts with our earlier
results demonstrating that wild-type BIMs displayed no selective
preference for BAX or BAK (Fig. 4c). Conversely, tBID encoding
the BIM BH3 domain lost any speciﬁcity, killing BAK- or
BAX-deleted cells equally well. Using a similar approach, we next
investigated whether the PUMA BH3 domain also dictated a
selective dependence for BAK. SVEC cells stably expressing
PUMABIM BH3 or BIMsPUMA BH3 together with BCL-xL were
generated (Fig. 6d) then BAX and/or BAK were deleted by
CRISPR/Cas9-based genome editing (Supplementary Fig. 5b).
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Mirroring our ﬁndings with tBID, engraftment of the BIM BH3-
domain into PUMA abolished its selective preference for BAK
(Fig. 6e). In the reciprocal swap, cells expressing BIM encoding
the PUMA BH3-domain failed to respond to ABT-737 treatment,
possibly due to reduced expression of the BIMPUMABH3 chimera
(Fig. 6d,e). Collectively, these data demonstrate that the
BH3-domain is a key determinant in deﬁning selectivity for BAX
or BAK.
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imaging using an IncuCyte imager (c) or by clonogenic survival assay (d). In c cell death was normalized to treated, empty CRISPR control for each line
(Control, each 100% cell death). Error bars represent the s.e.m. of 3 independent experiments (c) or s.d. of triplicate samples from a representative
experiment carried out twice independently (d). (e) BAK-deleted or reconstituted SVEC cells stably expressing FLAG-tBID 2A BCL-xL or FLAG-PUMA 2A
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death was calculated following normalization to treated control for each line (each 100% cell death). Errors bars represent the s.e.m. of three independent
experiments. (f) SVEC cells stably expressing FLAG-PUMA 2A BCL-xL were treated for 4 h with increasing concentrations of ABT-737. Cleavage of
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experiments. (h) Genome-edited HeLa cells stably expressing either eGFP-tBID, BIM or PUMA 2A BCL-xL were treated with 10mmol l 1 ABT-737 for 24 h
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empty control line. Errors bars represent the s.e.m. of three independent experiments. See also Supplementary Fig. 3.
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Discussion
In this study, we outline an effective means to render cells
addicted to anti-apoptotic Bcl-2 prosurvival function—a method
we call mito-priming. Following co-expression of pro- and
anti-apoptotic Bcl-2 family proteins, cells are highly sensitive to
Bcl-2 inhibition allowing BH3 mimetic treatment to trigger
apoptosis in a rapid manner. We demonstrate the utility of this
method to compare the speciﬁcity and potency of different BH3
mimetics. Moreover, using our approach, we ﬁnd that tBID and
PUMA, can display selectivity for BAK over BAX in the
activation of mitochondrial apoptosis. Our data demonstrate
that tBID and PUMA selectivity for BAK, whilst dictated
by the BH3-domain, is independent of anti-apoptotic Bcl-2
inhibition.
The rationale behind mito-priming is based on earlier ﬁndings
that some cancer cells are ‘primed for death’ and require
anti-apoptotic Bcl-2 function for survival5. Interestingly, ectopic
expression of Bcl-2 family members alone can facilitate apoptotic
priming in some settings thereby sensitizing cells to pro-death
triggers26,27. Nevertheless, anti-apoptotic Bcl-2 expression often
renders cells resistant to apoptotic stimuli. By simultaneously
co-expressing pro- and anti-apoptotic Bcl-2 proteins, our method
of mito-priming is broadly applicable to different cell types.
Furthermore, it allows rapid interrogation of speciﬁc BH3-only/
Bcl-2 combinations in the regulation of apoptosis. One potential
caveat of this method is that mito-priming is subject to
modulation by endogenous BH3-only proteins. Given the high-
level of exogenous BH3-only expression and the lack of response
of the unmodiﬁed cell lines used here to BH3 mimetics (thereby
indicating low BH3-only load) these effects may be negligible
(Fig. 1d–f)28. Nevertheless, to circumvent any inﬂuence of
endogenous BH3-only proteins, mito-priming could be applied
in BH3-only protein deﬁcient cells. Finally, the ability to easily
generate stably ‘mito-primed’ cell lines allows the induction of
apoptosis over the whole population in a synchronous manner
that is not easily achievable via other means.
Because of their central role in maintaining cell viability,
intense interest surrounds the targeting of anti-apoptotic Bcl-2
proteins in cancer. To date, the most effective inhibitors of Bcl-2
function are BH3 mimetics. As a monotherapy, BH3 mimetics
effectively kill cancer cells that are so-called ‘primed-to-die’. Due
to their high BH3-only protein load, primed-to-die cells require
anti-apoptotic Bcl-2 function for survival. By creating a Bcl-2
dependency in vitro, our method effectively phenocopies
primed-to-die cells such that addition of BH3 mimetic alone
leads to rapid cell death. In addition to using BH3 mimetics to
engage cell death, our method also provides a rapid and robust
means to screen BH3 mimetic potency and selectivity. Using this
approach we determined that ABT-199 and A-1331852 are the
most potent, currently available inhibitors of BCL-2 and BCL-xL,
respectively. Moreover, we identify UMI-77 and A-1210477 as
effective inhibitors of MCL-1 function in vitro, with A-1210477
displaying the greatest potency and selectivity.
It has recently been shown that tBID and BIM can display
selectivity for BAK over BAX in the engagement of MOMP and
apoptosis24. By combining our approach of induced Bcl-2
addiction with CRISPR/Cas9-based deletion of BAX or BAK, we
ﬁnd that PUMA, in addition to tBID, can also display selectivity
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for BAK. Selective dependence for BAK can be uncoupled from
BH3-only expression level, since BIMs displayed no selective
dependence yet was expressed at levels intermediate to tBID and
PUMA. The selective dependence of PUMA and tBID for BAK
appears to be independent of differential neutralization of
anti-apoptotic Bcl-2 function for two main reasons: (1) selective
preference of tBID and PUMA for BAK was maintained following
combined neutralization of BCL-2, BCL-xL and MCL-1
(Fig. 5b,c) and (2) BIM, which displays an anti-apoptotic Bcl-2
binding proﬁle similar to tBID and PUMA5,21,29, failed to display
any selectivity for BAK or BAX. Nevertheless, our data
demonstrate that the BH3-domain is the key determinant for
BAK selectivity by tBID and PUMA—engraftment of the tBID
BH3-domain into BIMs, imparted BAK selectivity on BIMs,
whereas engraftment of the BIM BH3-domain into tBID and
PUMA abolished selectivity (Fig. 6b–e). These ﬁndings support
previous data demonstrating that BH3-domain peptides alone
can display preference for either BAX or BAK24. In contrast to
these ﬁndings, a recent study using liposome and mitochondrial-
based permeabilization assays failed to observe BH3-only
preferences for BAX or BAK30. Why tBID and PUMA display
selectivity for BAK is currently unclear although it appears strictly
cell-type dependent. In this case of tBID we found that any
selective requirement for BAK was completely lost when
mitochondrial permeabilization was assayed using isolated
mitochondria. This ﬁnding, supported by others30, argues that
the factor(s) mediating selectivity may not solely be integral to
differences in Bcl-2 protein interactions.
In summary, by inducing Bcl-2 addiction, mito-priming
represents a facile and effective way to induce mitochondrial
apoptosis. Importantly, this approach avoids non-MOMP-
dependent effects inherent to commonly used apoptotic stimuli.
As such, this method should prove an ideal approach to study
Bcl-2 regulation of mitochondrial permeabilization, MOMP and
its downstream effects. Moreover, mito-priming is well suited for
various screening purposes, including the identiﬁcation and
characterization of Bcl-2 targeting compounds as well as novel
regulators of mitochondrial-dependent apoptosis.
Methods
BH3 mimetics and cell lines. WEHI-539, ABT-199,  263 and  737 were
obtained from Chemietek. UMI-77 was obtained from Selleckchem. ABT-737
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enantiomer, A-1210477, A-1155463 and A-1331852 were provided by Abbvie
Pharmaceuticals. Cell lines were obtained from the ATCC.
Molecular cloning and cell line generation. 2A constructs were directly cloned
into LZRS retroviral backbone between EcoRI and XhoI using Gibson Assembly
cloning kit (NEB #E5510S). Fragments for the various BH3-only and prosurvival
BCL2 members were ampliﬁed by PCR using Phusion High Fidelity polymerase
(Life Technologies #F530L) using appropriate human cDNAs as template. The P2A
sequence used in this work was: 50 GGATCCGGAGCCACGAACTTCTCTCTGT
TAAAGCAAGCAGGAGACGTGGAAGAAAACCCCGGTCCT-30 . Retroviruses
were produced using Ampho or Eco Phoenix 293T cells following transfection with
Lipofectamine 2000 (Life Technologies). Target cells were infected twice with viral
supernatant in the presence of polybrene (1 mgml 1) and then selected for 7 days
with Zeocin 200 mgml 1 (Life Technologies #R25001). GFP-positive cells were
then sorted on a BD FACSAria cell sorter. For CRISPR/Cas9-mediated deletion of
BAX and BAK, sgRNA sequences were selected using the MIT CRISPR design tool
(http://crispr.mit.edu/) and cloned into LentiCRISPRv2 backbone (Addgene
#52961). The following guide sequences were used: murine BAX: 50-CAACTTCA
ACTGGGGCCGCG-30(þ ) and BAK: 50-GCGCTACGACACAGAGTTCC-30( );
human BAX: 50-AGTAGAAAAGGGCGACAACC-30( ) and BAK: 50-GCCATG
CTGGTAGACGTGTA-30( ). Lentiviral production, cell infection and selection
were performed according to Zhang lab protocol31. shRNA sequences targeting
murine APAF-1 were GCGGATAAGAAGGTTAAGATT (sh1) and
CATGCTTATTTGCACTCTTTA (sh2).
Viability assays. For short-term viability assays, we used SYTOX Green dye
exclusion and live-cell imaging using an IncuCyte FLR imaging system (Essen
BioScience). Brieﬂy, 5 105 cells were plated into 12-well plates. The following day
cells were treated as described in the presence of 30 nM SYTOX Green (Life
Technologies). Plates were scanned every hour for 24 h, scanning 4 ﬁelds per well.
Percentage cell death was calculated by normalizing against maximal cell death
following BH3-mimetic treatment. Maximal cell death was calculated bv visual
inspection of Incucyte images, where percentage cell death¼ Sytox Green positive
cells/total cells (Sytox Green positive plus negative) 100. Alternatively, in some
experiments, 24-h treatment with 1 mM actinomycin D was used as 100% death
control. For cell death analysis by ﬂow-cytometry, cells were stained using Alexa
Fluor 647 Annexin V (BioLegend #640912) according to the manufacturer’s pro-
tocol and quantiﬁed on a BD FACSCalibur instrument. For clonogenic survival
assay, 800 cells stably expressing the construct of interest were plated into each well
of a 6-well tissue culture plate. The following days cells were treated with the
indicated stimuli. Ten days later, cells were stained with 1% Methylene Blue in
methanol/H2O (1:1 vol/vol). Following image capture, colonies were counted
automatically using Fiji software (http://ﬁji.sc/Fiji) and compared with untreated
cells (taken as 100% survival). Images were processed as followed: 1/ conversion
of scans into 8 bits images and threshold adjustment to remove background;
2/ separation of colonies using the Watershed tool; 3/ counting of colonies using
the Analyze Particles tool.
Microscopy. Confocal imaging was carried out using a Nikon A1R confocal
microscope (Nikon Instruments) with laser wavelengths of 405, 488, 561, and
636 nm. Images were acquired with a  60 NA 1.4 objective. Immunoﬂuorescence
staining for cytochrome c was performed as follows: SVEC cells stably expressing
GFP–tBID 2A BCL-xL and treated with ABT-737 as described in the ﬁgure legends
were ﬁxed in 4% PFA/PBS for 10min and permeabilized in 0.2% Triton/PBS for
15min followed by 1 h blocking in 2% BSA/PBS. The primary antibody and
cytochrome c (BD Biosciences, 556432, 1/300 in PBS) was incubated overnight.
AlexaFluor 647 was used as secondary antibody (Life Technologies, A21245, 1/300
in PBS). Cytochrome c was considered released from the mitochondria when it was
observed as diffused in the cytosol. For the colocalization studies, SVEC cells stably
or transiently expressing GFP–tBID 2A BCL-xL, GFP alone, histone GFP or mito
YFP were co-stained with MitoTracker Deep Red FM (ThermoFisher, M22426)
according to manufacturer’s instruction and then the Pearson’s coefﬁcient was
determined using ImageJ and JACoP plugin32. Cytochrome c was considered
released from the mitochondria when staining displayed a diffuse localization
(as opposed to punctate, mitochondrial localization). Cytochrome c release was
visually quantiﬁed by counting an average of 150 cells (6 different ﬁelds) per
condition. Error bars represent the s.e.m. of 3 independent experiments.
Mitochondrial permeabilization assay. Mitochondrial fractions were obtained
from cells harvested and centrifuged at 1,200g for 5min at 4 C. The cell pellet was
resuspended in s.e.m. Buffer (10mmol l 1 HEPES, 250mmol l 1 sucrose,
pH 7.2) supplemented with protease inhibitors and homogenized. Samples were
centrifuged at 500g for 3min at 4 C. The supernatant was transferred to a
new tube and subjected to a centrifugation step at 13,000g for 30min at 4 C.
Sedimented mitochondria were washed two times and incubated in the presence
or the absence of 100 nmol l 1 recombinant Bax and/or 10 nmol l 1 tBid
(BD Biosciences) and/or 10 mmol l 1 ABT-737 for 1 h at 37 C. Subsequently,
mitochondria and supernatant were separated by centrifugation at 13,000g for
5min. Both fractions were subjected to western blot analysis.
Immunoprecipitation. Protein lysates were prepared in ice-cold Triton-X 100 lysis
buffer (20mM Tris-Cl (pH 7.4), 135mM NaCl, 1.5mM MgCl2, 1mM EGTA,
10% glycerol, 1% Triton-X 100) supplemented with protease inhibitor and PMSF.
Lysates (0.5–1mg) were incubated with 20 ml anti-FLAG M2 afﬁnity gel (A2220,
Sigma) for 16 h at 4 C under end-over-end agitation. Anti-FLAG afﬁnity was then
washed ﬁve times by centrifugation in ice-cold Triton-X 100 lysis buffer, followed
by one wash in TBS (10mmol l 1 Tris-Cl (pH 7.4), 150mmol l 1 NaCl). Bound
protein complexes were then eluted in 100mgml 1 FLAG-peptide (A6002,
ApexBio) in TBS for 20min at room temperature, resuspended in Laemelli sample
buffer containing 10mmol l 1 DTT and boiled for 5min at 95 C before immu-
noblot analysis.
Antibodies. For western blotting the following antibodies were used all at 1:1,000
dilution unless otherwise stated; Cell Signaling: PARP (#9532), APAF-1 (#8723),
BAK (D4E4, #12105), and Hsp60 (#4870); from Abcam: active caspase 3
(#ab13847), BCL-xL (#ab32370, used at 1/500 dilution), BCL-2 (#ab18210, used at
1/500 dilution), and Mcl-1 (#ab32087, used at 1/500 dilution); from Santa Cruz:
TOM20 (#sc-11415) and BAX (N20, #sc-493); from others: actin (MP Biomedicals
#8691001, used at 1/10,000 dilution), Flag M2 (Sigma #F1804) and GFP (in house).
For immunoﬂuorescence: cytochrome c (BD #556432) was used (1/300 dilution).
MitoTracker Deep Red 647 (Life Technologies #M22426) was used at a 100 nM
ﬁnal concentration. Images were acquired on a Nikon A1R confocal instrument.
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